Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Medidata Solutions (MDSO) Share Price
Media coverage about Medidata Solutions (NASDAQ:MDSO) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medidata Solutions earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.9032919546379 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Medidata Solutions (MDSO) Quant Score Limit Rating – Investorplace.com (investorplace.com)
- Deutsche Bank Starts Medidata Solutions (MDSO) at Buy, ‘Revolutionizing the Clinical Landscape’ – StreetInsider.com (streetinsider.com)
- Medidata Solutions (MDSO) Coverage Initiated by Analysts at Deutsche Bank (americanbankingnews.com)
- Top Analyst Upgrades and Downgrades: Boston Scientific, Ciena, GoDaddy, Kratos, Lipocine, Repligen, Teladoc and More (247wallst.com)
- 2 Longs and 2 Shorts to Watch (minyanville.com)
MDSO has been the topic of several recent research reports. Jefferies Group reaffirmed a “hold” rating and set a $78.00 target price on shares of Medidata Solutions in a research note on Tuesday, August 22nd. KeyCorp reaffirmed a “buy” rating and set a $86.00 target price on shares of Medidata Solutions in a research note on Sunday, September 17th. Royal Bank of Canada initiated coverage on shares of Medidata Solutions in a research note on Tuesday, September 19th. They set a “sector perform” rating and a $82.00 target price on the stock. Zacks Investment Research raised shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. Finally, Wells Fargo & Company lowered their price target on shares of Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating on the stock in a research report on Friday, October 27th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $84.54.
Medidata Solutions (NASDAQ:MDSO) traded up $0.23 during midday trading on Monday, reaching $66.46. 332,202 shares of the company’s stock were exchanged, compared to its average volume of 543,669. Medidata Solutions has a 52 week low of $47.77 and a 52 week high of $85.92. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37. The firm has a market capitalization of $3,871.87, a PE ratio of 79.79, a P/E/G ratio of 4.12 and a beta of 1.69.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, October 26th. The company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The company had revenue of $140.08 million for the quarter, compared to analysts’ expectations of $141.27 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. Medidata Solutions’s revenue for the quarter was up 16.7% compared to the same quarter last year. equities research analysts anticipate that Medidata Solutions will post 0.77 EPS for the current fiscal year.
In other Medidata Solutions news, Director Robert Taylor sold 5,000 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $71.39, for a total value of $356,950.00. Following the transaction, the director now owns 49,372 shares of the company’s stock, valued at $3,524,667.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael I. Otner sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $70.88, for a total transaction of $708,800.00. Following the completion of the transaction, the executive vice president now directly owns 80,674 shares in the company, valued at approximately $5,718,173.12. The disclosure for this sale can be found here. Insiders sold 237,010 shares of company stock worth $16,305,136 in the last ninety days. 5.80% of the stock is currently owned by corporate insiders.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.